150 related articles for article (PubMed ID: 36594136)
1. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
Qiu JL; Luo SM; Yin WF; Li X; Zhou ZG
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(1):38-41. PubMed ID: 36594136
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J; Luo S; Yin W; Li X; Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):49-58. PubMed ID: 36935177
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A; Almuwais A; Gibbons H
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
[TBL] [Abstract][Full Text] [Related]
6. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
Ning P; Liu S; Cao H
J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Li S; Zhang Y; Sun Z; Hu J; Fang C
Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
[TBL] [Abstract][Full Text] [Related]
8. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
Maamari J; Yeung SJ; Chaftari PS
Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
10. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
Huang X; Yang M; Wang L; Li L; Zhong X
Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
Huang W; Liu Y; Li M; Xue Y; Bao W; Guo Y
Medicine (Baltimore); 2023 Nov; 102(45):e35946. PubMed ID: 37960733
[TBL] [Abstract][Full Text] [Related]
14. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
15. Type 1 diabetes related to immune checkpoint inhibitors.
Tachibana M; Imagawa A
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101657. PubMed ID: 35450793
[TBL] [Abstract][Full Text] [Related]
16. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
17. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
Kusuki K; Suzuki S; Mizuno Y
Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
[TBL] [Abstract][Full Text] [Related]
19. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
Edahiro R; Ishijima M; Kurebe H; Nishida K; Uenami T; Kanazu M; Akazawa Y; Yano Y; Mori M
Thorac Cancer; 2019 May; 10(5):1276-1279. PubMed ID: 30964601
[TBL] [Abstract][Full Text] [Related]
20. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
Okubo M; Hataya Y; Fujimoto K; Iwakura T; Matsuoka N
J Diabetes Investig; 2023 Jan; 14(1):147-150. PubMed ID: 36251515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]